| Product Code: ETC6749154 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 China Oncogene Inhibitors Market Overview |
3.1 China Country Macro Economic Indicators |
3.2 China Oncogene Inhibitors Market Revenues & Volume, 2021 & 2031F |
3.3 China Oncogene Inhibitors Market - Industry Life Cycle |
3.4 China Oncogene Inhibitors Market - Porter's Five Forces |
3.5 China Oncogene Inhibitors Market Revenues & Volume Share, By Genes, 2021 & 2031F |
3.6 China Oncogene Inhibitors Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.7 China Oncogene Inhibitors Market Revenues & Volume Share, By Treatment, 2021 & 2031F |
3.8 China Oncogene Inhibitors Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.9 China Oncogene Inhibitors Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.10 China Oncogene Inhibitors Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 China Oncogene Inhibitors Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer in China |
4.2.2 Growing investments in healthcare infrastructure and research development |
4.2.3 Technological advancements in oncogene inhibitors |
4.3 Market Restraints |
4.3.1 Stringent regulatory approval processes for oncogene inhibitors |
4.3.2 High costs associated with oncogene inhibitor therapies |
4.3.3 Limited access to advanced oncogene inhibitors in rural areas |
5 China Oncogene Inhibitors Market Trends |
6 China Oncogene Inhibitors Market, By Types |
6.1 China Oncogene Inhibitors Market, By Genes |
6.1.1 Overview and Analysis |
6.1.2 China Oncogene Inhibitors Market Revenues & Volume, By Genes, 2021- 2031F |
6.1.3 China Oncogene Inhibitors Market Revenues & Volume, By EGFR, 2021- 2031F |
6.1.4 China Oncogene Inhibitors Market Revenues & Volume, By HER, 2021- 2031F |
6.1.5 China Oncogene Inhibitors Market Revenues & Volume, By BRCA, 2021- 2031F |
6.1.6 China Oncogene Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.2 China Oncogene Inhibitors Market, By Indication |
6.2.1 Overview and Analysis |
6.2.2 China Oncogene Inhibitors Market Revenues & Volume, By Breast Cancer, 2021- 2031F |
6.2.3 China Oncogene Inhibitors Market Revenues & Volume, By Ovarian Cancer, 2021- 2031F |
6.2.4 China Oncogene Inhibitors Market Revenues & Volume, By Lung Cancer, 2021- 2031F |
6.2.5 China Oncogene Inhibitors Market Revenues & Volume, By Pancreas Cancer, 2021- 2031F |
6.2.6 China Oncogene Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.3 China Oncogene Inhibitors Market, By Treatment |
6.3.1 Overview and Analysis |
6.3.2 China Oncogene Inhibitors Market Revenues & Volume, By Platinum-Based Chemotherapy, 2021- 2031F |
6.3.3 China Oncogene Inhibitors Market Revenues & Volume, By PARP Inhibitors, 2021- 2031F |
6.3.4 China Oncogene Inhibitors Market Revenues & Volume, By Anti-HER Antibodies, 2021- 2031F |
6.3.5 China Oncogene Inhibitors Market Revenues & Volume, By EFGR Inhibitors, 2021- 2031F |
6.3.6 China Oncogene Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.4 China Oncogene Inhibitors Market, By Route of Administration |
6.4.1 Overview and Analysis |
6.4.2 China Oncogene Inhibitors Market Revenues & Volume, By Oral, 2021- 2031F |
6.4.3 China Oncogene Inhibitors Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.5 China Oncogene Inhibitors Market, By End-Users |
6.5.1 Overview and Analysis |
6.5.2 China Oncogene Inhibitors Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.5.3 China Oncogene Inhibitors Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.5.4 China Oncogene Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.6 China Oncogene Inhibitors Market, By Distribution Channel |
6.6.1 Overview and Analysis |
6.6.2 China Oncogene Inhibitors Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.6.3 China Oncogene Inhibitors Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.6.4 China Oncogene Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
7 China Oncogene Inhibitors Market Import-Export Trade Statistics |
7.1 China Oncogene Inhibitors Market Export to Major Countries |
7.2 China Oncogene Inhibitors Market Imports from Major Countries |
8 China Oncogene Inhibitors Market Key Performance Indicators |
8.1 Number of clinical trials for oncogene inhibitors in China |
8.2 Adoption rate of personalized medicine in cancer treatment |
8.3 Rate of approval for new oncogene inhibitors by Chinese regulatory authorities |
9 China Oncogene Inhibitors Market - Opportunity Assessment |
9.1 China Oncogene Inhibitors Market Opportunity Assessment, By Genes, 2021 & 2031F |
9.2 China Oncogene Inhibitors Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.3 China Oncogene Inhibitors Market Opportunity Assessment, By Treatment, 2021 & 2031F |
9.4 China Oncogene Inhibitors Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.5 China Oncogene Inhibitors Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.6 China Oncogene Inhibitors Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 China Oncogene Inhibitors Market - Competitive Landscape |
10.1 China Oncogene Inhibitors Market Revenue Share, By Companies, 2024 |
10.2 China Oncogene Inhibitors Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here